12 research outputs found
Recommended from our members
Corrigendum to "Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus". [Neuroscience 174 (2011) 50-63].
Recommended from our members
Corrigendum to "Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus". [Neuroscience 174 (2011) 50-63].
A case report of septic metastatic meningitis from Klebsiella pneumoniae liver abscess after hepaticojejunostomy for bile duct cancer
Expression of a Barhl1a reporter in subsets of retinal ganglion cells and commissural neurons of the developing zebrafish brain
Novel Applications and Future Perspectives of Nanocomposites
As the present chapter of the book is located in the concluding section, it was important to highlight the main applications of composite materials focusing especially on applications, which exploit other peculiarities of the materials besides photocatalysis. This will be done, by introducing those materials and their composites that are most studied, or were found to exhibit interesting behavior. In many of the presented cases, the main structural, morphological, or optical property of the given composite will be discussed to understand its functioning mechanism, and its role in the current scientific approaches. Additionally, this chapter aims to give a perspective regarding the composite-based nanoscience, and points out important research directions for the further developments of composite materials
The Endocannabinoid System: A Dynamic Signalling System at the Crossroads Between Metabolism and Disease
The discovery of the endocannabinoid system (ECS) in the early 1990s of last century generated high expectations of new therapeutic opportunities. Its central role and pleiotropic character seemed to offer promising indications in the fields of pain, inflammation, CNS disorders, weight management and metabolic diseases. However, around 2007 the tide began to turn when several cannabinoid receptor type 1 (CB1) antagonists/inverse agonists failed as therapeutics against overweight and its complications. More recently, the development of FAAH (Fatty Acid Amide Hydrolase) inhibitors against pain has also faced serious setbacks. In retrospect the much greater complexity of the ECS than originally assumed has played a fundamental role in these difficulties. Although there is no doubt that endocannabinoids and their receptors are of great (patho-)physiological relevance, it has become clear that the ECS is intimately intertwined with other biological systems. Endocannabinoids exist in equilibrium with fatty acids and their metabolic derivatives, including eicosanoids and prostamides. Furthermore, there are several biologically active analogues of endocannabinoids, in particular fatty acid amides, with metabolic pathways overlapping those of the ECS. Finally, endocannabinoids per se and their congeners show “promiscuous” behaviour going beyond interactions with CB1 and CB2 receptors. It has become clear that the complexity of what may be called the “endocannabinoidome” demands for pharmacological approaches that take into account these dynamics. Targeting the “endocannabinoidome” continues to offer opportunities for prevention and therapy, in particular for chronic diseases. However, chances for success are more likely to come from “multiple-target” than from “single-target” approaches